Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: The present disclosure relates to the discovery that certain ocular diseases may be treated using Edonentan crystalline forms. Specific Edonentan crystalline form can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, or an anti-VEGF agent. Using Edonentan crystalline forms, alone or in combination with an additional agent, provides increased perfusion to the retina or reduced TOP in certain ocular diseases and reduces damage to retinal cells.

Abstract: The present disclosure relates to the discovery that certain ocular diseases may be treated using Edonentan crystalline forms. Specific Edonentan crystalline form can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, or an anti-VEGF agent. Using Edonentan crystalline forms, alone or in combination with an additional agent, provides increased perfusion to the retina or reduced IOP in certain ocular diseases and reduces damage to retinal cells.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: The present invention is related to new derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to dihydroisoquinoline derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Abstract: The present disclosure relates to the discovery that certain ocular diseases may be treated using Edonentan crystalline forms. Specific Edonentan crystalline form can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, or an anti-VEGF agent. Using Edonentan crystalline forms, alone or in combination with an additional agent, provides increased perfusion to the retina or reduced IOP in certain ocular diseases and reduces damage to retinal cells.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: The present disclosure describes a system and method to classify optical coherence tomography (OCT) images. The present system can classify OCT images without first segmenting the retina tissue. The system can generate one or more profiles from vertical transects through the OCT images. The system can identify image statistics based on the one or more profiles. The system's classifier can then classify the OCT images based on the identified image statistics.

Abstract: A far infrared (“FIR”) sauna cabin equipped with a far infrared (“FIR”) heating elements constructed of ceramic, carbon, and/or light emitting diodes (“LED”), designed for therapeutic use in a sauna, capable of emitting far infrared energy, and heating an individual's skin for purposes of rejuvenation, anti-aging, weight loss, and acne therapy. The FIR heating element emits IR energy in a wavelength and frequency optimum for resonant absorption by the human body, resulting in the release of toxins stored within subcutaneous fatty deposits, which are then carried out of the person's system as he or she sweats. The FIR sauna is operated by a system comprising a local control system and a remote computer running access control software. A user account is configured containing a user's allowed privileges. When a user swipes an access card, the remote computer verifies the requested privilege. If allowed, the local system energizes the sauna system.

Abstract: The present disclosure describes a system and method to classify optical coherence tomography (OCT) images. The present system can classify OCT images without first segmenting the retina tissue. The system can generate one or more profiles from vertical transects through the OCT images. The system can identify image statistics based on the one or more profiles. The system's classifier can then classify the OCT images based on the identified image statistics.

Abstract: A far infrared (“FIR”) sauna cabin equipped with a far infrared (“FIR”) heating elements constructed of ceramic, carbon, and/or light emitting diodes (“LED”), designed for therapeutic use in a sauna, capable of emitting far infrared energy, and heating an individual's skin for purposes of rejuvenation, anti-aging, weight loss, and acne therapy. The FIR heating element emits IR energy in a wavelength and frequency optimum for resonant absorption by the human body, resulting in the release of toxins stored within subcutaneous fatty deposits, which are then carried out of the person's system as he or she sweats. The FIR sauna cabin is further equipped with necessary hardware and tools to effectively create a more flexible environment in which the user can change seating configurations, move about more freely and conduct stretching routines or exercises within the sauna cabin, using specialized fittings integrated to the interior of the sauna cabin.

Abstract: In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl -1,2,3,4-tetrahydroisoquinoline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating and/or preventing malaria. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Inhibitors of parasitic dihydroorotate dehydrogenase enzyme (DHOD) are candidate therapeutics for treating malaria. Illustrative of such therapeutic agents include the compound: and a triazolopyrimidine class of compounds that conform to Formula IX: and their solvates, stereoisomers, tautomers and pharmaceutically acceptable salts.

Abstract: In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating and/or preventing malaria. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Systems and methods for using memory usage to pinpoint sub-optimal code for gaming systems are provided herein. Memory usage characteristics, such as latency, cache misses, load-hit-store, memory address misuse, and wasted cache bandwidth are presented, preferably in a graphical format, to provide the developer with information for optimizing source code. A trace analysis is performed on source code undergoing optimization. Relevant data is extracted from the trace analysis, sorted as necessary, and presented to the user. The user may be presented with multiple results sorting mechanisms as well as ways to change the presentation of the results.

Abstract: A far infrared (“FIR”) sauna cabin equipped with a far infrared (“FIR”) heating elements constructed of ceramic, carbon, and/or light emitting diodes (“LED”), designed for therapeutic use in a sauna, capable of emitting far infrared energy, and heating an individual's skin for purposes of rejuvenation, anti-aging, weight loss, and acne therapy. The FIR heating element emits IR energy in a wavelength and frequency optimum for resonant absorption by the human body, resulting in the release of toxins stored within subcutaneous fatty deposits, which are then carried out of the person's system as he or she sweats. The FIR sauna cabin is further equipped with necessary hardware and tools to effectively create a more flexible environment in which the user can change seating configurations, move about more freely and conduct stretching routines or exercises within the sauna cabin, using specialized fittings integrated to the interior of the sauna cabin.

Abstract: A system and methods for providing shading effects include a shading network possessing the ability to create, maintain, and incrementally evolve shading techniques and effects. The shader network provides the ability to encapsulate CPU and GPU code into a self-contained node that can be transported between renderers. As a result, authors can develop reusable shading techniques that can express the wide range of effects available via utilization of CPU and GPU code. The shader network also provides the capability to compose multiple nodes into a reusable “macro” node that affords authors the ability to build derivative shading effects without the need to modify an application's renderer or constituent nodes.

Abstract: A high level shader language compiler incorporates transforms to optimize shader code for graphics processing hardware. An instruction reordering transform determines instruction encapsulations of dependent instructions that reduce concurrent register usage by the shader. A phase pulling transform re-organizes the shader's instructions into phases that reduce a measure of depth of texture loads. A register assigning transform assigns registers to lower register usage by the shader.